1	Inhibition of the beta-1 adrenergic receptor does not potentiate mirabegron-stimulated				
2	human brown adipose tissue thermogenesis.				
3 4 5	Lauralyne Dumont <sup>1,2</sup> , Alexandre Caron <sup>3,4,5</sup> , Gabriel Richard <sup>6</sup> , Etienne Croteau <sup>6</sup> , Mélanie Fortin <sup>1</sup> , Frédérique Frisch <sup>1</sup> , Serge Phoenix <sup>1,6</sup> , Stéphanie Dubreuil <sup>1</sup> , Brigitte Guérin <sup>6</sup> , Éric E. Turcotte <sup>6</sup> , André C. Carpentier <sup>1,7</sup> , Denis P. Blondin <sup>1,8, #</sup> .				
6 7 8	<sup>1</sup> Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada				
9 10 11 12	<ul> <li><sup>2</sup>Department of Physiology-Pharmacology, Université de Sherbrooke, Sherbrooke, QC, Canada.</li> <li><sup>3</sup>Faculty of Pharmacy, Université Laval, Quebec City, QC, Canada.</li> <li><sup>4</sup>Quebec Heart and Lung Institute, Quebec City, QC, Canada.</li> <li><sup>5</sup>Montreal Diabetes Research Center, Montreal, QC, Canada.</li> </ul>				
13	<sup>6</sup> Department of Nuclear Medicine and Radiobiology, Centre d'Imagerie Moléculaire de				
14 15 16	Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada. <sup>7</sup> Department of Medicine, Division of endocrinology, Université de Sherbrooke, Sherbrooke, OC, Canada				
10 17 18	QC, Canada <sup>8</sup> Department of Medicine, Division of neurology, Université de Sherbrooke, Sherbrooke, QC, Canada				
19 20 21	#Corresponding author				
22 23	Running Head:				
24	Word count Main Text: 3,316	Abstract: 148			
25 26 27	Number of tables: 2 Number of figures: 4				
28	Address correspondence to:				
	Dr. Denis P. Blondin	29			
	Centre de recherche du CHUS	30			
	Sherbrooke, Québec, Canada K1N 6N5 Tel: 819.346.1110 ext. 15243	31			
		32			
24	e-mail: <u>denis.p.blondin@usherbrooke.ca</u>	33			
34 25	Conflict of interests The conthese house				
33 26	Conflict of interest: The authors have declared that no conflict of interest exists related to				
30 27	the content of this manuscript.				
51					

## 1 ABSTRACT

2	Pharmacological stimulation of human brown adipose tissue (BAT) has been hindered by either
3	ineffective activation or undesirable off-target secondary effects. Oral administration of the
4	maximal allowable dose of mirabegron (200 mg), a $\beta_3$ -adrenergic receptor ( $\beta_3$ -AR) agonist, has
5	been effective in stimulating BAT thermogenesis and whole-body energy expenditure. However,
6	this too has been accompanied by undesirable cardiovascular effects. Combining mirabegron with
7	a cardio-selective $\beta_1$ -AR antagonist could not only suppress these unwanted effects, but potentially
8	increase the sensitivity of the $\beta_3$ -AR and $\beta_2$ -AR in WAT and BAT. Here we report that co-ingesting
9	a high dose of the $\beta_1$ -AR antagonist bisoprolol with mirabegron suppresses the increase in heart
10	rate, systolic blood pressure and myocardial oxygen consumption. However, it also blunted the
11	mirabegron-stimulated increase in BAT lipolysis, thermogenesis and glucose uptake. Whether the
12	attenuation in BAT blood flow induced by the large dose of bisoprolol limited BAT thermogenesis
13	remains to be determined.
14	clinicaltrials.gov (NCT04823442)
15	

16

Key Words : brown adipose tissue, thermogenesis, positron emission tomography, adrenergic
 receptor, stable isotope, adipose tissue, energy metabolism.

#### 1 INTRODUCTION

2 The stimulation of brown adipose tissue (BAT) thermogenesis has long been touted as an 3 attractive therapeutic target for the prevention or treatment of obesity and its cardiometabolic 4 complications. This stems primarily from the large body of work in preclinical models, which 5 robustly demonstrate the energy dissipating capacity of BAT following cold or pharmacological 6 stimulation <sup>1–5</sup>. However, evidence for BAT functioning in such a capacity remains controversial 7 <sup>6</sup> and largely associative in humans <sup>7,8</sup>. Some of the barriers in understanding the therapeutic 8 potential of human BAT relates to the stimuli used to activate BAT thermogenesis, which often 9 simultaneously recruits other thermogenic mechanisms. For instance, much of what is known 10 about human BAT function comes from cold-stimulated conditions, where thermogenesis and substrate clearance is primarily driven by shivering skeletal muscles <sup>9–12</sup>, even under very mild 11 12 conditions <sup>13</sup>. Alternatively, the recent repurposing of the  $\beta_3$ -adrenergic receptor ( $\beta_3$ -AR) agonist 13 mirabegron, a medication used to treat overactive bladder (OAB), has provided the opportunity to 14 isolate the metabolic effects of targeting BAT more specifically given its high affinity for the 15 human  $\beta_3$ -AR compared to the  $\beta_2$ - or  $\beta_1$ -AR (105-fold greater affinity for  $\beta_3$ -AR than  $\beta_1$ -AR, and 16 33-fold stronger than  $\beta_2$ -AR).

The initial investigations using mirabegron to stimulate BAT revealed two important trends <sup>14–18</sup>. First, stimulating BAT thermogenesis required a dosage that was four-times higher than the maximum approved dosage (approved for 50 mg daily) <sup>19</sup>. Only when mirabegron was ingested at the maximal allowable dose (200 mg) in lean healthy men did whole-body energy expenditure and BAT glucose uptake increase <sup>17,19</sup>. Furthermore, only the high dose of mirabegron increased BAT oxidative metabolism compared to room temperature, levels that remained significantly lower than what is observed during mild cold exposure <sup>19</sup>. Secondly, such a high dose of mirabegron led to

1 nonselective  $\beta$ -AR activation, resulting in an increase in cardiovascular responses ( $\beta_1$ -AR-2 mediated) and white adipose tissue (WAT) lipolysis (primarily  $\beta_2$ -AR-mediated). Indeed, both 3 heart rate and systolic blood pressure increased when given the maximal allowable dose of 4 mirabegron, consistent with the secondary effects reported in the early mirabegron clinical trials for the treatment of OAB  $^{20-22}$ . In humans, the heart expresses mainly the  $\beta_1$ -AR  $^{23,24}$  while brown 5 adipocytes express mainly the  $\beta_2$ -AR and  $\beta_1$ -AR and very low levels of  $\beta_3$ -AR <sup>19,25,26</sup>. This explains 6 7 why, despite its high affinity for the  $\beta_3$ -AR, mirabegron may still bind to the  $\beta_2$ -AR and  $\beta_1$ -AR to 8 stimulate thermogenesis. We also recently showed that silencing the gene encoding the  $\beta_2$ -AR 9 (ADRB2) in vitro, resulted in a compensatory increase in the expression of the gene encoding the 10  $\beta_3$ -AR (ADRB3)<sup>19</sup>. Similarly, others have shown that silencing the gene encoding for the  $\beta_1$ -AR 11 (ADRB1) significantly increases brown/beige adipocyte oxygen consumption, despite decreasing 12 UCP1 expression<sup>27</sup>. In light of these findings, the primary aim of this study was to examine 13 whether administration of the maximal allowable dose of mirabegron when combined with a 14 cardio-selective  $\beta_1$ -AR antagonist, bisoprolol, could increase the sensitivity of the  $\beta_3$ -AR and  $\beta_2$ -15 AR in WAT and BAT while suppressing the unwanted cardiovascular effects that present with the 16 administration of high doses of mirabegron. Thus, we hypothesized that administration of 17 mirabegron with a  $\beta_1$ -AR receptor antagonist could block cardiovascular effects while increasing 18 BAT thermogenesis above levels observed when mirabegron is administered alone.

19

#### 1 **RESULTS**

#### 2 The Beneficial Metabolic Responses Induced by Mirabegron Are Attenuated by Bisoprolol

3 The main purpose of this study was to compare the stimulation of BAT metabolism using 4 mirabegron without or with a  $\beta_1$ -AR antagonist in 8 lean healthy individuals (Table 1, Figure 1). 5 We hypothesized that the acute oral administration of the maximal allowable dose of mirabegron 6 (200 mg) with the  $\beta_1$ -AR antagonist, bisoprolol (10 mg), would result in an increase in BAT 7 oxidative metabolism and whole-body energy expenditure without the adverse cardiovascular 8 events observed when a high dose of mirabegron is administered alone. The primary outcome 9 measures of this clinical study as entered in clinicaltrials.gov (NCT04823442) included the change 10 in activation of BAT (oxidative metabolism and blood flow) and BAT net glucose uptake. 11 Secondary endpoints can be found at https://clinicaltrials.gov/ct2/show/NCT04823442.

12 Using liquid chromatography-tandem mass spectrometry we first examined the plasma 13 pharmacokinetics of mirabegron without (M) or with bisoprolol (MB) in the participants. The 14 study was designed to ensure that the time of maximal plasma mirabegron concentrations 15 coincided with our dynamic list-mode PET acquisition which was 240 minutes after oral 16 administration of the mirabegron without or with bisoprolol (Table 2 and Figure 2A; Median: M: 17 180 min; MB: 240 min). Compared to baseline measures, oral administration of either mirabegron 18 alone or in combination with bisoprolol increased resting energy expenditure by 27% (+18.2 ± 6.7 19 kcal/h; P < 0.0001) and 11% (+7.4 ± 8.1 kcal/h; P = 0.0268), respectively (Figure 2B; Table 2). 20 However, the resting energy expenditure was significantly lower when mirabegron was co-21 ingested with bisoprolol compared to when it was ingested alone (Figure 2 C; P = 0.0402).

A multi-tracer approach with [<sup>11</sup>C]acetate and the [<sup>18</sup>F]FDG was used to evaluate the rate of BAT
oxidative metabolism and tissue-specific glucose uptake. A four-compartment, two-tissue

pharmacokinetic model for  $[^{11}C]$  acetate in BAT<sup>28</sup> was applied to derive the rates of  $[^{11}C]$  acetate 1 uptake ( $K_1$ , mL·g<sup>-1</sup>·min<sup>-1</sup>), a marker of tissue perfusion, oxidative metabolism ( $k_2$ , min<sup>-1</sup>) and lipid 2 synthesis ( $k_3$ , min<sup>-1</sup>). The rate of BAT [<sup>11</sup>C]acetate uptake increased with mirabegron alone (Figure 3 4 2D; P = 0.0511), which was accompanied by a 2.7-fold increase in BAT oxidative metabolism (Figure 2E; from  $0.636 \pm 0.251$  min<sup>-1</sup> at room temperature to  $1.629 \pm 1.097$  min<sup>-1</sup> with mirabegron 5 6 alone, P = 0.0421). Nevertheless, BAT oxidative metabolism was not significantly different when 7 the mirabegron was co-ingested with the bisoprolol compared to control room temperature conditions (Figure 2E; from  $0.636 \pm 0.251$  min<sup>-1</sup> at room temperature to  $1.273 \pm 0.651$  min<sup>-1</sup>). We 8 9 found that mirabegron without or with bisoprolol did not elicit a significant increase in BAT 10 intracellular lipid synthesis (Figure 2F), nor elicit a difference in the change in CT-derived tissue 11 radiodensity, which represents a marker of changes in intracellular triglyceride content (Figure 12 2G). Using the Patlak linearization model, we showed that the high dose of mirabegron increased 13 the rate of BAT glucose uptake, but was significantly lower when combined with bisoprolol ( $24 \pm$ 10 nmol·g<sup>-1</sup>·min<sup>-1</sup> with mirabegron alone vs.  $16 \pm 8$  nmol·g<sup>-1</sup>·min<sup>-1</sup> with mirabegron and bisoprolol; 14 15 P = 0.0284). Although the rate of BAT glucose uptake was lower when mirabegron was given with 16 bisoprolol, it remained significantly greater than what has previously been reported under room temperature conditions  $[9 \pm 4 \text{ nmol} \cdot \text{g}^{-1} \cdot \text{min}^{-1}, N = 27; P = 0.0018^{29}]$ . We did not observe any 17 18 differences in net glucose uptake in subcutaneous WAT (scWAT;  $12 \pm 7 \text{ nmol} \cdot \text{g}^{-1} \cdot \text{min}^{-1}$  with mirabegron alone vs.  $13 \pm 4 \text{ nmol} \cdot \text{g}^{-1} \cdot \text{min}^{-1}$  with mirabegron combined with bisoprolol) or skeletal 19 muscles (from  $11 \pm 6 \text{ nmol} \cdot \text{g}^{-1} \cdot \text{min}^{-1}$  with mirabegron alone vs.  $10 \pm 1 \text{ nmol} \cdot \text{g}^{-1} \cdot \text{min}^{-1}$  with 20 21 mirabegron combined with bisoprolol) between the two conditions (Figure 2H).

#### 22 Bisoprolol Suppressed Cardiovascular Secondary Effects of Mirabegron

1 It has previously been demonstrated that administration of high doses of mirabegron leads to unwanted cardiovascular effects, likely mediated through a cross-activation of the  $\beta_1$ -AR <sup>17,18,30,31</sup>. 2 3 These undesirable effects are what prompted us to assess cardiovascular outcomes when combining mirabegron with the cardioselective  $\beta_1$ -AR antagonist, bisoprolol <sup>32</sup>. Mirabegron alone 4 5 increased systolic blood pressure by  $5 \pm 5$  mmHg above baseline levels. In contrast, when 6 mirabegron was combined with bisoprolol, systolic blood pressure decreased below baseline levels 7 by  $6 \pm 10$  mmHg (Figure 3A, P = 0.0252). Diastolic blood pressure decreased by  $3 \pm 6$  mmHg and 8  $4 \pm 19$  mmHg below pre-treatment levels with mirabegron alone or with bisoprolol, respectively, 9 with no significant difference between the two conditions (Figure 3B). Mirabegron given alone 10 increased heart rate by  $6 \pm 7$  beats min<sup>-1</sup> (P = 0.0565) above pre-treatment levels, whereas mirabegron administered with bisoprolol decreased heart rate by  $5 \pm 6$  beats min<sup>-1</sup> (P = 0.1302) 11 12 below the pre-treatment levels (Figure 3C, P = 0.0081). To examine the effects of mirabegron with 13 or without bisoprolol on the myocardial metabolic demands, we calculated the rate pressure 14 product (RPP). While RPP increased significantly by  $972 \pm 927$  mmHg bpm above pre-treatment 15 levels (P = 0.0333) when given mirabegron alone, it decreased by  $1548 \pm 1158 \text{ mmHg}\cdot\text{bpm}$ 16 compared to pre-treatment levels when mirabegron was administered with bisoprolol (P = 0.0544) 17 which was significantly different between the two conditions (Figure 3D, P = 0.0005).

As result of the large field of view of the PET scanner (26 cm), it was possible for the first time to simultaneously quantify BAT thermogenesis and myocardial oxygen consumption in humans. Myocardial blood flow (F), tracer uptake ( $K_1$ ) and oxidative metabolism ( $k_2$ ) were assessed by [<sup>11</sup>C]acetate PET in three segments of the heart vascularized by the left anterior descending artery (LAD), left circumflex artery (LCX), and right coronary artery (RCA) as well as globally (total), pre- and post-treatment (Figure 3E, 3F, and 3G). In order to do this, we analyzed PET dynamic

1 images of the heart with the PMOD cardiac PET modeling tool, PCARDP (PMOD Technologies, 2 version 3.7). However, since the PET scanner has a limited field of view and participants varied 3 in height, we prioritized PET image acquisition of supraclavicular BAT at the expense of having 4 the complete image of the heart. Therefore, we have a limited number of PET images for the 5 analysis of the heart, which did not allow a complete statistical analysis. However, based on the 6  $[^{11}C]$  acetate data, myocardial blood flow did not appear to be affected by mirabegron, whether 7 administered alone or with bisoprolol, when compared to pre-treatment conditions, in all the regions of the heart (Figure 3E). The  $[^{11}C]$  acetate uptake in the heart increased when given 8 9 mirabegron compared to pre-treatment levels and increased further in combination with the 10 bisoprolol (Figure 3F). The oxidative metabolism of the three segments of the myocardium as well 11 as global myocardium oxidative metabolism were more elevated in the pre-treatment condition 12 and when mirabegron was given alone compared to the administration of mirabegron with 13 bisoprolol. The reduction in oxidative metabolism when mirabegron was administered in 14 combination with bisoprolol is consistent with the reduction in RPP, which is commonly used as 15 an index of myocardial oxygen consumption <sup>33,34</sup>.

#### 16 Mirabegron Without or With Bisoprolol Did Not Alter White Adipose Tissue Lipolysis

Since the high dose of mirabegron leads to nonselective  $\beta$ -AR activation, we assessed white adipose tissue (WAT) lipolysis which is primarily driven by  $\beta_2/\beta_1$ -AR signaling. To examine this response we used continuous infusion of [U-<sup>13</sup>C]palmitate and [1,1,2,3,3-<sub>2</sub>H<sup>5</sup>]-glycerol to determine the rate of systemic appearance of NEFA and glycerol (indicator of whole-body WAT lipolysis) (Figure 4A-4D). The systemic appearance rate (R<sub>a</sub>) of glycerol (Ra<sub>glycerol</sub>) and NEFA (Ra<sub>NEFA</sub>) did not increase significantly (Figure 4A-4D). However, compared to the baseline period, the rate of fatty acid oxidation increased significantly both when mirabegron was given alone (P

1 = 0.0021) and when given in combination with bisoprolol (P = 0.0038) (Figure 4F), however there 2 was no significant difference between the two conditions. In steady-state conditions, the difference 3 between the total fatty acids released upon intracellular hydrolysis of triglycerides (3 X Ragiverol) 4 and the rate of total fatty acid oxidation (calculated from indirect calorimetry) indicate the whole-5 body rate of fatty acid re-esterification, as this is primarily its alternative metabolic fate. Since the 6 increase in both the rate of whole-body lipolysis and fatty acid oxidation were not different whether 7 mirabegron was given alone or with bisoprolol, this suggests that there was no difference in fatty 8 acid re-esterification between the two groups (Figure 4I). Indeed, there was no change in the re-9 esterification of the fatty acids at the primary site of lipolysis (intracellular cycling) or following 10 their transit in circulation where they can be taken up by the liver to be stored in intracellular lipid 11 droplets or incorporated into VLDL (extracellular cycling) (Figure 4I).

12

#### 13 **DISCUSSION**

14 The ingestion of the  $\beta_3$ -AR agonist mirabegron at the maximal allowable dose (200 mg) 15 increases BAT thermogenesis but also leads to an adverse overstimulation of cardiovascular responses, likely by stimulating all three  $\beta$ -AR subtypes <sup>17,18,30,31</sup>. Here we show that combining 16 17 the administration of mirabegron with a cardioselective  $\beta_1$ -AR antagonist (bisoprolo); 15-fold more selective for  $\beta_1$ -AR vs  $\beta_2$ -AR and 31-fold more selective for  $\beta_1$ -AR vs  $\beta_3$ -AR<sup>35</sup>), to suppress 18 19 these cardiovascular responses, did not increase BAT oxidative metabolism, and in fact reduced 20 BAT blood flow. This was also accompanied by a reduction in the rate of BAT glucose uptake. 21 By design, bisoprolol did indeed inhibit the mirabegron-stimulated increase in systolic blood pressure and heart rate. It is unclear whether the attenuation of systemic and BAT blood flow 22

induced by the relatively large dose of bisoprolol used may have contributed to the impaired BAT
 thermogenesis.

3 Previously, we showed that oral administration of the maximal allowable dose of 4 mirabegron (200 mg) increases BAT oxidative metabolism on average 2.1-fold above basal 5 conditions. This was also accompanied by a 17% increase in whole-body energy expenditure <sup>19</sup>. 6 The aim of the present study was, first, to examine whether giving this same dose of mirabegron 7 in combination with a cardioselective  $\beta_1$ -AR antagonist could increase BAT oxidative metabolism 8 while blunting the cardiovascular responses. We were also interested in determining whether 9 inhibiting the  $\beta_1$ -AR could increase the sensitivity of the  $\beta_2$ - and  $\beta_3$ -AR. We previously showed 10 that silencing the ADRB2 in vitro resulted in a compensatory increase in the expression of ADRB3 11 <sup>19</sup>. We therefore hypothesized that inhibiting the  $\beta_1$ -AR would not only prevent the undesirable 12 cardiovascular responses, but also increase the stimulation of the  $\beta_2$ -AR and  $\beta_3$ -AR, thereby 13 allowing mirabegron to be administered at a lower or similar dose while eliciting similar or greater 14 thermogenic effects. Indeed, whether mirabegron was administered alone or in combination with 15 bisoprolol, energy expenditure increased above baseline levels (by 27% with mirabegron alone 16 and 11% with mirabegron and bisoprolol). Similar to our previous investigation, BAT oxidative 17 metabolism and BAT blood flow increased with the high dose of mirabegron administration. 18 However, in contrast to our hypothesis, this effect was blunted when mirabegron was administered 19 with bisoprolol. The exact cause of this reduction in BAT oxidative metabolism remains unclear. 20 One explanation could be that  $\beta_1$ -AR inhibition, rather than potentiating the effect of mirabegron, 21 directly inhibited BAT oxidative metabolism. This would certainly be consistent with a previous 22 in vitro study, which showed that silencing ADRB1 in immortalized human brown adipocytes significantly attenuated UCP1 induction in response to isoproterenol stimulation <sup>36</sup>. However, we 23

1 and others have shown that silencing ADRB1 in human primary brown adjocytes has no effect on cellular respiration, whether stimulated with norepinephrine <sup>19</sup> or not <sup>37</sup>. Alternatively, a more 2 3 plausible explanation is that the reduction in BAT blood flow when mirabegron was given with 4 bisoprolol restricted the ability for BAT to increase oxidative metabolism. Although adrenergic 5 stimulation can increase BAT blood flow, even in the absence of thermogenesis in mice <sup>38</sup> and humans<sup>39</sup>, the suppression of BAT blood flow in male Wistar rats has been shown to significantly 6 7 reduce the norepinephrine-stimulated increase in BAT temperature <sup>40</sup>. Evidence from the present 8 study suggest this may also be the case in humans.

9 Whether this reduction in BAT blood flow is a direct effect of  $\beta_1$ -AR-antagonism on BAT 10 vasomotor tone or an indirect result of a possible decrease in cardiac output remains unclear. The 11 rate of glucose uptake was also reduced when bisoprolol was given with mirabegron, which may 12 have been partially mediated by the reduction in BAT blood flow. It should be noted that the rate 13 of glucose uptake was still significantly greater than what has been reported under unstimulated room temperature conditions  $(16 \pm 8 \text{ nmol} \cdot \text{g}^{-1} \cdot \text{min}^{-1} \text{ with mirabegron} + \text{bisoprolol vs } 9 \pm 4 \text{ nmol} \cdot \text{g}^{-1} \cdot \text{min}^{-1} \text{ with mirabegron} + \text{bisoprolol vs } 9 \pm 4 \text{ nmol} \cdot \text{g}^{-1} \cdot \text{min}^{-1} \cdot \text{min}^{-1} \text{ with mirabegron} + \text{bisoprolol vs } 9 \pm 4 \text{ nmol} \cdot \text{g}^{-1} \cdot \text{min}^{-1} \cdot \text{min}^{-1} \text{ with mirabegron} + \text{bisoprolol vs } 9 \pm 4 \text{ nmol} \cdot \text{g}^{-1} \cdot \text{min}^{-1} \cdot \text{min}^{-$ 14 <sup>1</sup>·min<sup>-1</sup> at room temperature; <sup>41</sup>) or when given a therapeutic dose (50 mg) of mirabegron (9  $\pm$  5 15  $nmol \cdot g^{-1} \cdot min^{-1}; {}^{19})$ 16

One noted secondary effect of mirabegron administration is the increase in systolic blood pressure and heart rate when it is administered at the maximal allowable dose. Consistent with previous findings, the administration of the maximal allowable dose of mirabegron increased systolic blood pressure and heart rate by  $5 \pm 5$  mmHg and  $6 \pm 7$  beats·min<sup>-1</sup> above pre-treatment levels, respectively. In contrast, when mirabegron was given with bisoprolol, heart rate and rate pressure product (RPP), an indicator of myocardial oxygen consumption, decreased below baseline levels. The reduction in RPP agrees with the results obtained by [<sup>11</sup>C]acetate PET imaging of the myocardium performed in a sub-group of participants, which showed a global reduction in myocardial oxidative metabolism with bisoprolol. All these results were expected given the cardioselective nature of the  $\beta_1$ -AR antagonist used. The question remains whether this decrease in myocardial metabolism and cardiovascular responses contributed to the reduction in BAT thermogenesis.

6 In our previous investigation, we demonstrated that oral administration of mirabegron, not only 7 stimulated BAT thermogenesis, but also increased the systemic rate of appearance of NEFA and 8 glycerol, an indicator of whole-body WAT lipolysis, by 115% and 126%, respectively <sup>19</sup>. The 9 increased WAT lipolysis far exceeded the rate of whole-body fatty acid oxidation. This suggested 10 that a significant proportion of the fatty acids released following the hydrolysis of intracellular 11 triglycerides were likely re-esterified in situ. We estimated that this energetically-costly 12 triglyceride hydrolysis-fatty acid re-esterification cycle, commonly referred to as the triglyceride-13 fatty acid (TAG-FA) cycle or glycerolipid-free fatty acid (GL-FFA) cycle, accounted for 55% of 14 the mirabegron-stimulated increase in energy expenditure. In the present study, we did not observe 15 a significant increase in the systemic appearance of glycerol and NEFA. Consequently, we did not observe significant changes in the TAG-FA cycle and therefore it was likely a minor contributor 16 17 to the increase in energy expenditure in the present study, accounting for 5.6% of the increase in 18 energy expenditure following mirabegron administration alone, and 19.6% when mirabegron was 19 given with bisoprolol. The slightly lower whole-body energy expenditure with mirabegron and 20 bisoprolol administration was also accompanied by a decrease in carbohydrate utilization, which 21 might reflect the transient decrease in the systemic rate of appearance of glucose.

22

#### 23 **LIMITATIONS OF THE STUDY**

1 There are a few limitations to consider in the interpretation of our findings. First, this study 2 included a small number of young, healthy men. Only male participants were recruited, as the dose 3 given to stimulate BAT was 2-fold greater than the maximal allowable limit permitted for women 4 <sup>31</sup>. In women, the ingestion of mirabegron is associated with a dose-dependent prolongation of the 5 OTc interval, thus restricting the maximum allowable dose to 100 mg. Further work is needed to 6 examine whether there are sex-dependent differences in mirabegron-mediated activation of BAT 7 metabolism. Second, the high dose of bisoprolol used significantly decreased heart rate and the 8 systolic blood pressure below baseline levels, which could have contributed to the observed 9 reduction in BAT blood flow and could have limited the ability to stimulate BAT thermogenesis. The significant reduction in cardiovascular responses was somewhat limiting as there were 10 11 concerns with inducing significant levels of bradycardia. Indeed, of the 9 participants recruited 12 one participant with a particularly low resting heart rate (45 bpm) was precluded from completing 13 the mirabegron + bisoprolol condition as there were concerns about further decreasing his heart 14 rate. Finally, the PET/CT scanner used in the present study has a relatively large field of view (26 15 cm), which for the first time, allowed for the simultaneous quantification of BAT thermogenesis 16 and myocardial oxygen consumption in humans. However, in some of our taller participants, it 17 was not possible to image both the BAT and heart and therefore we prioritized the acquisition of supraclavicular BAT. This resulted in an incomplete dataset of the  $[^{11}C]$  acetate PET 18 19 pharmacokinetic analysis of the myocardium.

#### 20 CONCLUSION

In conclusion, as demonstrated in our previous study, a single maximal allowable dose of mirabegron elicited a significant increase in human BAT thermogenesis and whole-body energy expenditure. In contrast to our initial hypothesis, the addition of bisoprolol did reduce mirabegron-

- 1 stimulated BAT oxidative metabolism. Whether the attenuation in BAT blood flow induced by the
- 2 large dose of bisoprolol led to this reduction in mirabegron-stimulated BAT thermogenesis
- 3 remains to be determined. Further work is needed to determine the optimal pharmacological
- 4 approach to activate BAT thermogenesis in humans.

#### 1 Acknowledgements

2 The authors would like to thank the participants of this study for their commitment and 3 collaboration. The authors thank Caroll-Lynn Thibodeau, Maude Gérard, Myriam Flipot, Éric 4 Lavallée, Esteban Espinosa, Christophe Noll and Lucie Bouffard for their excellent technical 5 assistance and Stephen C. Cunnane for the use of PMOD. This work was supported by the Québec 6 Network on Drug Research (RORM), to A.Caron and D.P.Blondin as well as a grant from the 7 Natural Sciences and Engineering Research Council of Canada (NSERC Canada) to D.P.Blondin 8 (RGPIN-2019-05813). D.P. Blondin holds the GSK Chair in Diabetes of the Université de 9 Sherbrooke and a Fonds de Recherche du Québec-Santé (FRQS) J1 salary award. L. Dumont is 10 the recipient of an FRQS doctoral training award. A. Caron is supported by a Canada Research 11 Chair in Neurometabolic Pharmacology and an FRQS J1 salary award. A.C. Carpentier is 12 supported by a Canada Research Chair in the Molecular Imaging of Diabetes.

# 1 Author Contributions

- 2 Conceptualization, D.P.B and A.C.; Methodology, L.D., D.P.B, A.C., E.E.T., and A.C.C.;
- 3 Investigation, L.D., A.C., G.R., E.C., M.F., F.F., S.P., S.D., B.G., E.E.T., A.C.C., and D.P.B.;
- 4 Writing first draft, L.D. and D.P.B; Writing review and editing, L.D., A.C., G.R., E.C., M.F.,
- 5 F.F., S.P., S.D., B.G., E.E.T., A.C.C., and D.P.B.; Visualization, L.D. and D.P.B; Funding
- 6 Acquisition, A.C. and D.P.B.

7

- 8 Declaration of interests: No conflicts of interest, financial or otherwise, related to this work are
- 9 declared by the authors.

#### 1 FIGURES

#### 2 Figure 1. Study protocol.

3 (A) Randomized crossover study (n=8) where participants received mirabegron (200 mg) without

4 or with bisoprolol (10 mg), with a one-week wash-out period between visits.

- 5 (B) Metabolic protocol for both study visits.
- 6

Figure 2. Mirabegron increases BAT oxidative metabolism and glucose uptake but not in
combination with bisoprolol.

9 (A) Circulating mirabegron levels following oral administration of mirabegron (M, 200 mg) 10 without or with bisoprolol (MB, 10 mg) in humans. [ $^{11}$ C]acetate (orange arrow) and 2-deoxy-2-11 [ $^{18}$ F]-fluoro-D-glucose ([ $^{18}$ F]FDG, green arrow) radiotracers were injected 210 and 240 min after 12 oral administration of mirabegron or mirabegron + bisoprolol, respectively, followed by a dynamic 13 list-mode PET acquisition (n = 8).

14 (B and C) Whole body energy expenditure over time (B) and change from basal levels (C) in

15 response to oral administration of mirabegron (M, 200 mg) without or with bisoprolol (MB,10 mg)

(n = 8). The effect of intervention was determined using two-way ANOVA for repeated-measures

17 with Bonferroni post hoc test. #  $P \le 0.05$ ,  $\ddagger P \le 0.0001$ .

18 (D-F) [<sup>11</sup>C]acetate uptake rate (D,  $K_1$ ), oxidative metabolism (E,  $k_2$ ) and lipid synthesis (F,  $k_3$ ) of

19 supraclavicular BAT at baseline (Control) and in response to oral administration of mirabegron

- 20 (M, 200 mg) without or with bisoprolol (MB, 10 mg). Outliers were identify using the Interquartile
- 21 Range Method. One outlier (white square) was detected and replaced by the mean of this group
- and a previous study<sup>42</sup>.

1 (G) Change in supraclavicular BAT radiodensity from basal levels in responses to oral 2 administration of mirabegron (M, 200 mg) without or with bisoprolol (MB, 10 mg) (n = 8). 3 (H) Supraclavicular BAT, WAT, and skeletal muscle net glucose uptake in response to oral 4 administration of mirabegron (M, 200 mg) without or with bisoprolol (MB, 10 mg) (n = 8). Skeletal 5 muscle glucose uptake represents mean uptake of regions of interest drawn from *m. pectoralis* 6 major, m. trapezius, m. deltoideus, m. sternocleidomastoid, m. levator scapulae, m. latissimus 7 dorsi, and m. erector spinae. (I) Cervico-thoracic PET images of [<sup>11</sup>C]acetate (two right images) and [<sup>18</sup>F]FDG uptake in 8 9 response to oral administration of mirabegron (M, 200 mg) without or with bisoprolol (MB, 10 mg). PET images of [<sup>11</sup>C]acetate taken at 210 min and [<sup>18</sup>F]FDG taken at 240 min in the same 10 11 participant are depicted in response to mirabegron without or with bisoprolol. White arrows 12 represent supraclavicular BAT depot and orange arrows represent heart. Data presented as mean ± SD. A One-way ANOVA for repeated measures with Bonferroni post 13 14 hoc test was used to determine statistically significant differences between the basal and the two 15 treatment conditions. Difference between mirabegron without or with bisoprolol determined using 16 paired-sample t test.

17

Figure 3. Mirabegron with bisoprolol suppressed the cardiovascular side effects of
 mirabegron alone.

20 (A-C) Change in systolic blood pressure (A), diastolic blood pressure (B), and heart rate (C) from
21 basal levels in response to oral administration of mirabegron (M, 200 mg) without or with
22 bisoprolol (MB,10 mg) (n = 8).

1 (D) Change in rate pressure product from basal levels in response to oral administration of 2 mirabegron (M, 200 mg) without or with bisoprolol (MB, 10 mg) (n = 8). The effect of intervention 3 was determined using two-way ANOVA for repeated-measures with Bonferroni post hoc test. # P 4  $\leq 0.05$ . (E) Blood flow (F) obtained from the  $[^{11}C]$  acetate analysis of three segments (LAD, RCA and 5 6 LCX) of the heart and total heart (Global) at baseline (Control) and in response to oral 7 administration of mirabegron (M, 200 mg) without or with bisoprolol (MB, 10 mg) (n = 5-6). 8 (F)  $[^{11}C]$  acetate uptake  $(K_l)$  of three segments (LAD, RCA and LCX) of the heart and total heart 9 (Global) at baseline (Control) and in response to oral administration of mirabegron (M, 200 mg) 10 without or with bisoprolol (MB, 10 mg) (n = 5-6). (G) Oxidative metabolism ( $k_2$ )obtained from the [<sup>11</sup>C]acetate analysis of three segments (LAD, 11 12 RCA and LCX) of the heart and total heart (Global) at baseline (Control) and in response to oral 13 administration of mirabegron (M, 200 mg) without or with bisoprolol (MB, 10 mg) (n = 5-6). 14 LAD: Left anterior descending artery; LCX: Left circumflex artery; RCA: Right coronary artery. 15 Data presented as mean  $\pm$  SD. Difference between mirabegron without or with bisoprolol 16 determined using paired-sample t test 17

# Figure 4. Mirabegron alone or in combination with bisoprolol did not impact the TAG/NEFA cvcling.

(A and B) Change in systemic rate of appearance of glycerol over time (A) and change from basal
levels (B) in response to oral administration of mirabegron (M, 200 mg) without or with bisoprolol
(MB,10 mg) as index of whole-body lipolysis (n = 8).

1 (C and D) Change in systemic rate of appearance of NEFA over time (C) and change from basal 2 levels (D) in response to oral administration of mirabegron (M, 200 mg) without or with bisoprolol 3 (MB, 10 mg) (n = 8).4 (E and F) Change in whole-body fatty acid oxidation over time (E) and change from basal levels 5 (F) in response to of mirabegron (M, 200 mg) without or with bisoprolol (MB,10 mg) determined 6 by indirect calorimetry (n = 8). The effect of the intervention was determined using two-way 7 ANOVA for repeated-measures with Bonferroni post hoc test. #  $P \le 0.05$ , §  $P \le 0.001$ . 8 (G and H) Change in whole-body glucose utilization over time (G) and change from basal levels 9 (H) in response to mirabegron (M, 200 mg) without or with bisoprolol (MB,10 mg) determined by 10 indirect calorimetry (n = 8). The effect of intervention was determined using two-way ANOVA 11 for repeated-measures with Bonferroni post hoc test. #  $P \le 0.05$ , §  $P \le 0.001$ 12 (I) Change in total, intracellular, and extracellular triacylglycerol/fatty acid (TAG/FA) cycling 13 from basal levels in response to of mirabegron (M, 200 mg) without or with bisoprolol (MB,10 14 mg) (n = 8). 15 (J) Change in the energetic cost of total TAG/FA cycle (n = 8).

16 Data presented as mean ± SD. Difference between mirabegron without or with bisoprolol
17 determined using paired-sample t test.

## 1 STAR METHODS

# 2 KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER			
Biological Samples					
Human plasma samples	This paper	N/A			
Human urine samples	This paper	N/A			
Chemicals, Peptides, and Recombinant	t Proteins				
Myrbetriq (Mirabegron)	Astellas Pharma	N/A			
Bisoprolol	Sandoz Canada	N/A			
Critical commercial Assays	I				
Glycerol reagent set	Instruchemie, Sigma-Aldrich	Cat# 2913, Cat# F6428			
NEFA C kit	Wako diagnotics, Randox laboratories	Cat# 434-91795, Cat# FA115			
Software and Algorithms					
GraphPad Prism 8 for statistical	GraphPad Software	RRID: SCR_002798			
analysis					
Adobe Photoshop	Adobe	https://www.adobe.com/			
PMOD 3.7	PMOD Technologies LLC	RRID : SCR_016547			
MATLAB R2019a	The MathWorks	RRID : SCR_001622			
Other					
[ <sup>11</sup> C]acetate, radiotracer	CIMS	N/A			
[ <sup>18</sup> F]FDG, radiotracer	CIMS	N/A			
[6,6- <sup>2</sup> H <sub>2</sub> ]-glucose, stable isotope tracer	ACP Chemicals	Cat# 1CDLM349			
[U- <sup>13</sup> C]-palmitate, stable isotope tracer	Cambridge isotopes Laboratories	Cat# DLM-1229			
[1,1,2,3,3- <sup>2</sup> H <sub>5</sub> ]-glycerol, stable isotope	Cambridge isotopes Laboratories	Cat# DLM-1229			
tracer					
Vmax 29n (indirect calorimetry)	Sensormedics	N/A			
Biograph Vision PET-CT scanner	Siemens Healthineers	N/A			

3

#### 1 **RESOURCE AVAILABILITY**

#### 2 Lead contact

3 Further information and requests for resources and reagent should be directed to and will be

4 fulfilled by the lead contact, Denis P. Blondin (denis.p.blondin@usherbrooke.ca).

5

#### 6 Data and code availability

7 The processed data generated during this study as well as the MATLAB code used to perform the [<sup>18</sup>F]FDG 8 [<sup>11</sup>C]acetate pharmacokinetic modeling of and are available at 9 doi.org/10.5281/zenodo.5834789. Anonymized image files are voluminous and, therefore, not 10 deposited in any public repository, but can be made available on request to the lead contact 11 (denis.p.blondin@usherbrooke.ca).

12

#### 13 EXPIRIMENTAL MODEL AND SUBJECT DETAILS

#### 14 Human Subjects

15 Eight healthy men aged  $27 \pm 3$  years with a body mass index of  $22.5 \pm 1.7$  km/m<sup>2</sup>, body mass of 74.1  $\pm$  3<5.8 kg and body surface area of 2.27  $\pm$  0.09 m<sup>2</sup> participated in this study. All participants 16 17 were informed of the methodology and informed written consent was obtained in accordance with 18 the Declaration of Helsinki. The protocol was approved by the Human Ethics Committee of the 19 Centre de recherche du Centre hospitalier universitaire de Sherbrooke and Health Canada provided 20 regulatory approval for the off-label use of mirabegron. The study was pre-registered on 21 ClinicalTrials.gov (NCT04823442). The inclusion criteria included: (i) male; (ii) age between 18 and 35 years; (iii) BMI < 30 kg/m<sup>2</sup>; (iv) normal fasting glucose (< 5.6 mmol/l); (v) normal glucose 22 23 tolerance (2 h post 75 g OGTT glucose < 7.8 mmol/l); (vi) HbA1c < 5.8%. Exclusion criteria

1 included: (i) overt cardiovascular disease as assessed by medical history, physical exam, and 2 abnormal ECG; (ii) treatment with any drug known to affect lipid or carbohydrate metabolism; 3 (iii) presence of liver disease, uncontrolled thyroid disorder, previous pancreatitis, bleeding 4 disorder, or other major illness; (iv) smoking (>1 cigarette/day) and/or consumption of 2 alcoholic 5 beverages per day; (v) prior history or current fasting plasma cholesterol level > 7 mmol/l or fasting 6 TG > 6 mmol/l.

7

#### 8 METHOD DETAILS

#### 9 **Experimental Protocols**

10 Participants took part in two experimental sessions assigned in a random order. Participants 11 ingested either 200 mg of the  $\beta_3$ -AR agonist mirabegron (Myrbetriq, Astellas Pharma Canada) 12 alone or in combination with 10 mg of bisoprolol, a  $\beta_1$ -AR antagonist. Each experimental session 13 consisted of a baseline period at ambient temperature ( $\sim 22^{\circ}$ C), followed by the oral administration 14 of the medication. In the mirabegron + bisoprolol condition, both medications were given 15 simultaneously, as the bisoprolol monogram provide to the FDA reports a t<sub>max</sub> of 168 min, which 16 is 40 min earlier than the  $t_{max}$  of mirabegron (210 min). This would allow us to elicit the effects of 17  $\beta_1$ -AR antagonism prior to the full effect of mirabegron-mediated agonism. Experimental sessions 18 were conducted between 08.00 and 16.00 h at the Centre de recherche du Centre hospitalier 19 universitaire de Sherbrooke, following a 12 h fast and 48 h without strenuous physical activity. 20 Participants followed a 2-day standard isocaloric diet which was determined following 3-day food 21 record, accounting for the participant's standard daily physical activity level, determined by 22 wearing a portable arm band accelerometer for 3-days. Upon arriving to the laboratory, participants

- 1 emptied their bladder, then were weighed and indwelling catheters were placed in the antecubital
- 2 vein in both arms for blood sampling and tracer infusion.

#### 3 Metabolic Heat Production, Fuel Selection and Cardiovascular Measures

4 Whole-body metabolic heat production and substrate utilization was determined by indirect 5 respiratory calorimetry (corrected for protein oxidation), measured every 60 min for a collection period of 20 min<sup>7</sup>. The molar rate of fatty acid oxidation (µmol·min<sup>-1</sup>) was calculated from 6 triglyceride oxidation  $(g \cdot min^{-1})$  assuming the average molecular weight of triglyceride as 861 7  $g \cdot mol^{-1}$  and multiplying the molar rate of triglyceride oxidation by three, as three moles of fatty 8 acids are contained in each mole of triglyceride. Energy potentials of 16.3, 40.8 and 19.7 kJ·g<sup>-1</sup> 9 10 were used to calculate the amount of heat produced from glucose, lipid and protein oxidation, 11 respectively. Blood pressure and heart rate were measured every 60 min using an Omron blood 12 pressure monitor (HEM-790IT, Omron Healthcare).

#### 13 **PET Imaging and Analysis**

14 Participants remained supine in a PET and CT scanner (Siemens Healthineers Biograph Vision) 15 for 30 min for the baseline and the final 90 min of the mirabegron treatment. Tissue-specific 16 oxidative metabolism was determined by first performing a CT scan (30 mAs) centered at the 17 cervico-thoracic region to correct for attenuation and define PET regions of interest (ROI). At time 18 -45 min (room temperature, before treatment) and at time 210 min (*i.e.* 210 min following oral 19 administration of mirabegron alone or in combination with bisoprolol), a ~ 175 MBg bolus of <sup>11</sup>Clacetate was injected intravenously and was followed by a 20-min list-mode dynamic PET 20 acquisition (frames: 24 x 10 s, 12 x 30 s, 2 x 300 s) centered at the cervico-thoracic junction <sup>7</sup>. A 21 ~125 MBg bolus of 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG) was intravenously injected 30 22 min after the  $[^{11}C]$  acetate injection at time 240 (*i.e.* 240 min following oral administration of 23

mirabegron alone or in combination with bisoprolol). followed by a list-mode dynamic PET acquisition (frames:  $12 \times 10 \text{ s}$ ,  $10 \times 45 \text{ s}$ ,  $7 \times 90 \text{ s}$ ,  $2 \times 300 \text{ s}$ ) centered at the cervico-thoracic junction. Residual [<sup>11</sup>C]acetate activity prior to the [<sup>18</sup>F]FDG scans were corrected by acquiring a 30 s frame prior to the injection of [<sup>18</sup>F]FDG and accounting for the disintegration rate and metabolic clearance of <sup>11</sup>C.

ROI were drawn from the transaxial CT slices then copied to the  $[^{11}C]$  acetate and  $[^{18}F]$ FDG PET 6 7 images. ROIs were drawn in the left ventricle for blood activity (image-derived arterial input 8 function, AIF), the larger skeletal muscles in the field of view (e.g. m. sternocleidomastoid, m. 9 trapezius, m. pectoralis major, m. deltoideus, m. levator scapulae, m. latissimus dorsi, m. erector 10 spinea), on posterior cervical subcutaneous adipose tissue and on supraclavicular BAT. The mean 11 standard uptake values (SUV<sub>mean</sub>) from these ROIs were then extracted for each time frame using 12 PMOD (version 3.7, PMOD Technologies LLC) to create time-activity curves. The blood signal for [<sup>11</sup>C]acetate was then corrected to exclude the contribution of metabolites <sup>43</sup>. The metabolite-13 14 corrected time-activity curves were then used to perform pharmacokinetic modeling in MATLAB (The mathWorks, R2019a). A four-compartment, two-tissue, model<sup>28</sup> was applied to the 15 [<sup>11</sup>C]acetate signal to derive the rates of uptake ( $K_1$  in ml·g<sup>-1</sup>·min<sup>-1</sup>), oxidation ( $k_2$  in min<sup>-1</sup>) and 16 lipid synthesis ( $k_3$  in min<sup>-1</sup>). Plasma and tissue time-radioactivity curves for [<sup>18</sup>F]FDG were 17 18 analyzed graphically using the Patlak linearization method <sup>7</sup>. The glucose fractional uptake ( $K_i$  in 19 min<sup>-1</sup>) is equal to the slope of the plot in the graphical analysis. Net glucose uptake ( $K_m$  in nmol·g<sup>-</sup> 20 <sup>1</sup>·min<sup>-1</sup> = ( $K_i$ ·circulating glucose)·(LC<sup>-1</sup>)·(tissue density·1000)<sup>-1</sup>) was obtained by multiplying Ki by 21 circulating plasma glucose levels at the time of the PET image acquisition, which assumes a lump 22 constant (LC) value of 1.14 and 1.16 compared with endogenous plasma glucose for the BAT and 23 skeletal muscles, respectively, and corrected for a tissue density of 0.925 g/mL and 1.0597 g/mL.

#### 1 Whole-Body Lipolysis and Triacylglycerol/Fatty Acid Cycling

2 Upon arriving to the laboratory, participants emptied their bladder and indwelling catheters were 3 placed in the antecubital vein in both arms for blood sampling and tracer infusions. A primed (30 4  $\mu$ mol/kg) continuous infusion (0.3  $\mu$ mol·kg<sup>-1</sup>·min<sup>-1</sup>) of [6,6-<sup>2</sup>H<sub>2</sub>]-glucose was started 150 min 5 before oral administration of mirabegron or the combination of mirabegron and bisoprolol (time -6 150 min) to determine the systemic rate of appearance of plasma glucose (Raglucose)<sup>7</sup>. Plasma 7 NEFA appearance rate (Ra<sub>NEFA</sub>) and plasma glycerol appearance rate (Ra<sub>glycerol</sub>) were determined 8 with a continuous infusion of  $[U^{-13}C]$ -palmitate (0.01 µmol/kg/min in 100 mL 25% human serum 9 albumin) and a primed (1.6  $\mu$ mol·kg<sup>-1</sup>) continuous infusion (0.05  $\mu$ mol/kg/min) of [1,1,2,3,3-<sup>2</sup>H<sub>5</sub>]-10 glycerol started 60 min before the oral administration of mirabegron or the combination of mirabegron and bisoprolol (time - 60 min)<sup>7</sup>. Ra<sub>NEFA</sub> was calculated by multiplying the plasma 11 12 palmitate appearance rate by the fractional contribution of palmitate to total plasma NEFA 13 concentrations.

14 Total, intracellular and extracellular triacylglycerol/fatty acid (TAG/FA) cycling was calculated 15 using Ragiverol, RaNEFA and the rate of fatty acid oxidation. In brief, total TAG/FA cycling was 16 calculated as the difference between the rate of fatty acid oxidation and the total amount of fatty 17 acids made available by the hydrolysis of intracellular triglycerides (3 x Raglycerol), which is derived 18 primarily from WAT under fasted conditions. Since glycerol kinase has a low activity in WAT, 19 relative to other tissues, the glycerol produced following the complete hydrolysis of a triglyceride 20 in WAT is rapidly excreted into circulation where it can serve as gluconeogenic substrate. 21 Intracellular or primary TAG/FA cycling refers to the re-esterification of fatty acids within the cell 22 where it was hydrolyzed. This is calculated from the difference between the systemic rate of 23 appearance of NEFA (i.e. Ra<sub>NEFA</sub>) and the total amount of fatty acids released following

1 intracellular hydrolysis of triglycerides (3 x Ragiverol). Extracellular or secondary TAG/FA cycling 2 refers to the re-esterification of fatty acids after it has been released into the circulation, primarily 3 packaged by the liver into triglyceride-rich lipoproteins (very-low density lipoproteins; VLDL) or 4 intracellular lipid droplets. This is calculated from the difference between the total rate of fatty 5 acids oxidation and the systemic appearance of fatty acids (i.e. Ra<sub>NEFA</sub>). The energy cost of 6 TAG/FA cycling was calculated assuming that the re-esterification of each triglyceride requires 7 ~8 ATP (or ~144 kcal·mol<sup>-1</sup> of triglyceride recycled), for the activation of each of the three fatty 8 acids (2 ATP per fatty acid), and glycerogenesis (~2 ATP) providing the three-carbon backbone 9 for triglyceride synthesis<sup>44</sup>.

10

#### 11 **Biological Assays**

Glucose, total NEFA, TG, cortisol, TSH, free T3 and free T4 were measured using specific radioimmunoassay and colorimetric assays <sup>7</sup>. Plasma C-peptide, GIP, total GLP-1, glucagon, insulin, leptin and PYY were measured using Luminex xMAP-based immunoassays (Milllipore, Etobicoke, ON, Canada). Adiponectin, total and acylated ghrelin were measured by ELISA (Alpco, Salem, NH, USA). Individual plasma NEFA (palmitate, linoleate, oleate), [U-<sup>13</sup>C]palmitate enrichment, [1,1,2,3,3-<sup>2</sup>H<sub>5</sub>]-glycerol enrichment and [6,6-<sup>2</sup>H<sub>2</sub>]-glucose enrichment were measured by gas chromatography-mass spectrometry <sup>7</sup>.

19

#### 20 QUANTIFICATION AND STATISTICAL ANALYSIS

#### 21 Statistical Analyses

Statistical analysis was performed using Prism (GraphPad; 8.0). Blood chemistry data are
expressed as mean with 95% CI or median with interquartile range otherwise the data are expressed

1 as mean  $\pm$  SD. The Shapiro-Wilk test was performed to verify the normality of data, when

- 2 necessary. Significance between groups was determined using 2-tailed paired Student's t test, or
- 3 one-way or two-way ANOVA when appropriate, with multiple comparisons using Bonferroni's
- 4 correction. The significance threshold was set at  $P \le 0.05$ .

### 5 ADDITIONAL RESOURCES

- 6 ClinicalTrials.gov identifier NCT04823442
- 7
- 8

## REFERENCES

- Cannon, B., and Nedergaard, J. (2004). Brown Adipose Tissue: Function and
   Physiological Significance. Physiol Rev 84, 277–359. 10.1152/physrev.00015.2003.
- 5 2. Trayhurn, P. (1979). Thermoregulation in the diabetic-obese (db/db) mouse. Pflugers Arch
  6 380, 227–232. 10.1007/BF00582901.
- Stanford, K.I., Middelbeek, R.J.W., Townsend, K.L., An, D., Nygaard, E.B., Hitchcox,
  K.M., Markan, K.R., Nakano, K., Hirshman, M.F., Tseng, Y.-H., et al. (2013). Brown
  adipose tissue regulates glucose homeostasis and insulin sensitivity. Journal of Clinical
  Investigation *123*, 215–223. 10.1172/JCI62308.
- Feldmann, H.M., Golozoubova, V., Cannon, B., and Nedergaard, J. (2009). UCP1
   Ablation Induces Obesity and Abolishes Diet-Induced Thermogenesis in Mice Exempt
   from Thermal Stress by Living at Thermoneutrality. Cell Metab 9, 203–209.
   10.1016/j.cmet.2008.12.014.
- Berbée, J.F.P., Boon, M.R., Khedoe, P.P.S.J., Bartelt, A., Schlein, C., Worthmann, A.,
   Kooijman, S., Hoeke, G., Mol, I.M., John, C., et al. (2015). Brown fat activation reduces
   hypercholesterolaemia and protects from atherosclerosis development. Nat Commun 6,
   6356. 10.1038/ncomms7356.
- Carpentier, A.C., Blondin, D.P., Haman, F., and Richard, D. (2022). Brown adipose tissue
   a translational perspective. Endocr Rev. 10.1210/endrev/bnac015.
- 7. Ouellet, V., Labbé, S.M., Blondin, D.P., Phoenix, S., Guérin, B., Haman, F., Turcotte,
   E.E., Richard, D., and Carpentier, A.C. (2012). Brown adipose tissue oxidative
   metabolism contributes to energy expenditure during acute cold exposure in humans. J
   Clin Invest *122*, 545–552. 10.1172/JCI60433.
- Becher, T., Palanisamy, S., Kramer, D.J., Eljalby, M., Marx, S.J., Wibmer, A.G., Butler,
   S.D., Jiang, C.S., Vaughan, R., Schöder, H., et al. (2021). Brown adipose tissue is
   associated with cardiometabolic health. Nat Med 27, 58–65. 10.1038/s41591-020-1126-7.
- Blondin, D.P., Labbé, S.M., Noll, C., Kunach, M., Phoenix, S., Guérin, B., Turcotte, É.E.,
   Haman, F., Richard, D., and Carpentier, A.C. (2015). Selective Impairment of Glucose but
   Not Fatty Acid or Oxidative Metabolism in Brown Adipose Tissue of Subjects With Type
   2 Diabetes. Diabetes 64, 2388–2397. 10.2337/db14-1651.
- Blondin, D.P., Labbé, S.M., Phoenix, S., Guérin, B., Turcotte, É.E., Richard, D.,
  Carpentier, A.C., and Haman, F. (2015). Contributions of white and brown adipose tissues
  and skeletal muscles to acute cold-induced metabolic responses in healthy men. J Physiol *593*, 701–714. 10.1113/jphysiol.2014.283598.
- Blondin, D.P., Tingelstad, H.C., Noll, C., Frisch, F., Phoenix, S., Guérin, B., Turcotte,
  É.E., Richard, D., Haman, F., and Carpentier, A.C. (2017). Dietary fatty acid metabolism
  of brown adipose tissue in cold-acclimated men. Nat Commun 8, 14146.
  10.1038/ncomms14146.
- 40 12. u Din, M., Raiko, J., Saari, T., Kudomi, N., Tolvanen, T., Oikonen, V., Teuho, J., Sipilä,
  41 H.T., Savisto, N., Parkkola, R., et al. (2016). Human brown adipose tissue [150]O2 PET
  42 imaging in the presence and absence of cold stimulus. Eur J Nucl Med Mol Imaging *43*,
  43 1878–1886. 10.1007/s00259-016-3364-y.
- Hanssen, M.J.W., Hoeks, J., Brans, B., van der Lans, A.A.J.J., Schaart, G., van den
  Driessche, J.J., Jörgensen, J.A., Boekschoten, M. v, Hesselink, M.K.C., Havekes, B., et al.

1		(2015). Short-term cold acclimation improves insulin sensitivity in patients with type 2
2		diabetes mellitus. Nat Med 21, 863–865. 10.1038/nm.3891.
3	14.	Finlin, B.S., Memetimin, H., Confides, A.L., Kasza, I., Zhu, B., Vekaria, H.J., Harfmann,
4		B., Jones, K.A., Johnson, Z.R., Westgate, P.M., et al. (2018). Human adipose beiging in
5		response to cold and mirabegron. JCI Insight 3. 10.1172/jci.insight.121510.
6	15.	Finlin, B.S., Memetimin, H., Zhu, B., Confides, A.L., Vekaria, H.J., el Khouli, R.H.,
7		Johnson, Z.R., Westgate, P.M., Chen, J., Morris, A.J., et al. (2020). The $\beta$ 3-adrenergic
8		receptor agonist mirabegron improves glucose homeostasis in obese humans. J Clin Invest
9	1	<i>130</i> , 2319–2331. 10.1172/JCI134892.
10	16.	O'Mara, A.E., Johnson, J.W., Linderman, J.D., Brychta, R.J., McGehee, S., Fletcher,
		L.A., Fink, Y.A., Kapuria, D., Cassimatis, T.M., Kelsey, N., et al. (2020). Chronic
12		mirabegron treatment increases human brown fat, HDL cholesterol, and insulin
13	17	sensitivity. J Clin Invest $130, 2209-2219. 10.1172/JC1131126.$
14	17.	Cypess, A.M., Weiner, L.S., Roberts-Toler, C., Franquet Elia, E., Kessler, S.H., Kahn,
15		P.A., English, J., Chatman, K., Trauger, S.A., Doria, A., et al. (2015). Activation of
16		human brown adipose tissue by a $\beta$ 3-adrenergic receptor agonist. Cell Metab 21, 33–38.
17/ 10	10	10.1016/j.cmet.2014.12.009.
18	18.	Baskin, A.S., Linderman, J.D., Brychta, R.J., McGehee, S., Anflick-Chames, E., Cero, C.,
19		Johnson, J. W., O'Mara, A.E., Fletcher, L.A., Leitner, B.P., et al. (2018). Regulation of
20		Human Adipose Tissue Activation, Galibladder Size, and Bile Acid Metabolism by a p3-
21	10	Adrenergic Receptor Agonist. Diabetes 0/, 2113–2125. 10.2337/db18-0462.
22	19.	Blondin, D.P., Nielsen, S., Kuipers, E.N., Severinsen, M.C., Jensen, V.H., Miard, S.,
23		Jespersen, N.Z., Kooljinan, S., Boon, M.R., Fortin, M., et al. (2020). Human Brown
24 25		Adipocyte Thermogenesis is Driven by p2-AR Stimulation. Cell Metab 32, 287-300.e7.
25	20	10.1010/J.cmel.2020.07.005.
20	20.	in the management of everystive bladder. Ther A dy Line 4, 215, 224
21		10 1177/1756287212457114
20 20	21	10.11///1/J020/2124J/114.
29 30	21.	(2017) An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-
31		Induced Cardiovascular Effects I Clin Pharmacol 57, 1534, 1544, 10, 1002/ionh 952
32	22	Malik M van Gelderen F.M. Lee I.H. Kowalski D.I. Ven M. Goldwater R
33	22.	Mujajs S K Schaddelee M P de Koning P Kajbara A et al (2012) Proarrhythmic
34		safety of repeat doses of mirabegron in healthy subjects: a randomized double-blind
35		placebo-, and active-controlled thorough OT study. Clin Pharmacol Ther 92, 696–706
36		10 1038/clpt 2012 181
37	23	Ihl-Vahl, R. (1996). Differential Regulation of mRNA Specific for 61- and 62-adrenergic
38	20.	Receptors in Human Failing Hearts, Evaluation of the Absolute Cardiac mRNA Levels by
39		Two Independent Methods, J Mol Cell Cardiol 28, 1–10, 10,1006/imcc,1996.0001.
40	24.	Schobesberger, S., Wright, P.T., Poulet, C., Sanchez Alonso Mardones, J.L., Mansfield,
41		C., Friebe, A., Harding, S.E., Balligand, JL., Nikolaev, V.O., and Gorelik, J. (2020). 63-
42		Adrenoceptor redistribution impairs NO/cGMP/PDE2 signalling in failing
43		cardiomyocytes. Elife 9. 10.7554/eLife.52221.
44	25.	Arch, J.R.S. (2011). Challenges in $\beta_3$ -adrenoceptor agonist drug development. Ther Adv
45		Endocrinol Metab 2, 59–64. 10.1177/2042018811398517.

- Tran, K.-V., Brown, E.L., DeSouza, T., Jespersen, N.Z., Nandrup-Bus, C., Yang, Q.,
   Yang, Z., Desai, A., Min, S.Y., Rojas-Rodriguez, R., et al. (2020). Human thermogenic
   adipocyte regulation by the long noncoding RNA LINC00473. Nat Metab 2, 397–412.
   10.1038/s42255-020-0205-x.
- 5 27. Cero, C., Lea, H.J., Zhu, K.Y., Shamsi, F., Tseng, Y.-H., and Cypess, A.M. (2021). β3 6 Adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis.
   7 JCI Insight 6. 10.1172/jci.insight.139160.
- 8 28. Richard, M.A., Blondin, D.P., Noll, C., Lebel, R., Lepage, M., and Carpentier, A.C.
  9 (2019). Determination of a pharmacokinetic model for [11C]-acetate in brown adipose
  10 tissue. EJNMMI Res 9, 31. 10.1186/s13550-019-0497-6.
- Orava, J., Nuutila, P., Lidell, M.E., Oikonen, V., Noponen, T., Viljanen, T., Scheinin, M.,
  Taittonen, M., Niemi, T., Enerbäck, S., et al. (2011). Different metabolic responses of
  human brown adipose tissue to activation by cold and insulin. Cell Metab *14*, 272–279.
  10.1016/j.cmet.2011.06.012.
- 30. O'Mara, A.E., Johnson, J.W., Linderman, J.D., Brychta, R.J., McGehee, S., Fletcher,
  L.A., Fink, Y.A., Kapuria, D., Cassimatis, T.M., Kelsey, N., et al. (2020). Chronic
  mirabegron treatment increases human brown fat, HDL cholesterol, and insulin
  sensitivity. Journal of Clinical Investigation *130*, 2209–2219. 10.1172/JCI131126.
- 19 31. FDA (2012). Advisory committee briefing document mirabegron (YM178) for the
   20 treatment of overactive bladder.
- 21 32. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. (1999).
  22 Lancet 353, 9–13.
- 33. Nelson, R.R., Gobel, F.L., Jorgensen, C.R., Wang, K., Wang, Y., and Taylor, H.L. (1974).
  Hemodynamic predictors of myocardial oxygen consumption during static and dynamic
  exercise. Circulation *50*, 1179–1189. 10.1161/01.cir.50.6.1179.
- 34. Gobel, F.L., Norstrom, L.A., Nelson, R.R., Jorgensen, C.R., and Wang, Y. (1978). The
  rate-pressure product as an index of myocardial oxygen consumption during exercise in
  patients with angina pectoris. Circulation 57, 549–556. 10.1161/01.CIR.57.3.549.
- 2935.Schnabel, P., Maack, C., Mies, F., Tyroller, S., Scheer, A., and Böhm, M. (2000). Binding30Properties of β-Blockers at Recombinant  $\beta$ 1-,  $\beta$ 2-, and  $\beta$ 3-Adrenoceptors. J Cardiovasc31Pharmacol 36, 466–471. 10.1097/00005344-200010000-00008.
- 36. Riis-Vestergaard, M.J., Richelsen, B., Bruun, J.M., Li, W., Hansen, J.B., and Pedersen,
  S.B. (2020). Beta-1 and Not Beta-3 Adrenergic Receptors May Be the Primary Regulator
  of Human Brown Adipocyte Metabolism. J Clin Endocrinol Metab *105*, e994–e1005.
  10.1210/clinem/dgz298.
- 36 37. Cero, C., Lea, H.J., Zhu, K.Y., Shamsi, F., Tseng, Y.-H., and Cypess, A.M. (2021). β3 37 Adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis.
   38 JCI Insight 6. 10.1172/jci.insight.139160.
- 38. Abreu-Vieira, G., Hagberg, C.E., Spalding, K.L., Cannon, B., and Nedergaard, J. (2015).
  Adrenergically stimulated blood flow in brown adipose tissue is not dependent on
  thermogenesis. Am J Physiol Endocrinol Metab *308*, E822-9.
  10.1152/aipendo.00494.2014
- 42 10.1152/ajpendo.00494.2014.
- 43 39. Blondin, D.P., Frisch, F., Phoenix, S., Guérin, B., Turcotte, É.E., Haman, F., Richard, D.,
  44 and Carpentier, A.C. (2017). Inhibition of Intracellular Triglyceride Lipolysis Suppresses
- 45 Cold-Induced Brown Adipose Tissue Metabolism and Increases Shivering in Humans.
- 46 Cell Metab 25, 438–447. 10.1016/j.cmet.2016.12.005.

- 40. Nagashima, T., Ohinata, H., and Kuroshima, A. (1994). Involvement of nitric oxide in noradrenaline-induced increase in blood flow through brown adipose tissue. Life Sci 54, 17–25. 10.1016/0024-3205(94)00573-7.
- 4 41. Orava, J., Nuutila, P., Lidell, M.E., Oikonen, V., Noponen, T., Viljanen, T., Scheinin, M.,
  5 Taittonen, M., Niemi, T., Enerbäck, S., et al. (2011). Different metabolic responses of
  6 human brown adipose tissue to activation by cold and insulin. Cell Metab *14*, 272–279.
  7 10.1016/j.cmet.2011.06.012.
- Richard, G., Blondin, D.P., Syed, S.A., Rossi, L., Fontes, M.E., Fortin, M., Phoenix, S.,
  Frisch, F., Dubreuil, S., Guérin, B., et al. (2022). High-fructose feeding suppresses coldstimulated brown adipose tissue glucose uptake independently of changes in
  thermogenesis and the gut microbiome. Cell Rep Med *3*, 100742.
  10.1016/j.xcrm.2022.100742.
- 43. Buck, A., Wolpers, H.G., Hutchins, G.D., Savas, V., Mangner, T.J., Nguyen, N., and
  Schwaiger, M. (1991). Effect of carbon-11-acetate recirculation on estimates of
  myocardial oxygen consumption by PET. J Nucl Med *32*, 1950–1957.
- 44. Wolfe, R.R., and Chinkes, D.L. (2005). Isotope Tracers in Metabolic Research: Principles
  and Practice of Kinetic Analysis (Wiley-Liss).
- 18















Table 1. Participant characteristics

Participant Characteristics	Healthy men
N	8
Age (years)	$27 \pm 3$
Height (cm)	$181.5\pm3.9$
Mass (kg)	$74.1\pm5.8$
BMI (kg/m <sup>2</sup> )	$22.5\pm1.7$
Fat mass (kg)	$19.6\pm5.3$
Lean mass (kg)	$53.5\pm6.1$
Waist circumference (cm)	$80.8\pm6.9$
Hip circumference (cm)	$98.4\pm4.0$
Body fat (%)	$26.6\pm5.3$

BMI, Body Mass Index

Data expressed as mean  $\pm$  SD

	Mirabegron		Mirabegron + Bisoprolol	
	Baseline	Intervention	Baseline	Intervention
EE (kcal/h)	68.2 (63.9-72.6)	86.4 (79.4-93.5) <sup>b</sup>	71.1 (66.1-76.1)	77.1 (65.3-88.9)
Raglucose	1,147 (681-1,614)	741 (385-1,096) <sup>b</sup>	1,054 (681-1,426)	580 (267-894) <sup>b</sup>
(µmol/min)				
Glucose	4.6 (4.3-4.9)	4.3 (4.0-4.6) <sup>a</sup>	4.5 (4.4-4.6)	4.3 (4.1-4.5)
(mmol/L)				
NEFA	295 (199-391)	700 (539-861) <sup>b</sup>	270 (165-375)	715 (503-927) <sup>b</sup>
(umol/L)				
TG	0.7 (0.5-0.8)	$0.5 (0.4 - 0.6)^{b}$	0.7 (0.6-0.8)	$0.6 (0.5 - 0.8)^d$
(mmol/L)	50.0 (01.0.00.5)			52 0 (15 0 00 0)
Insulin	59.9 (21.3-98.6)	65.9 (21.7-110.2)	62.7 (23.4-102.0)	52.9 (15.9-89.8)
(pmol/L)	20.0(1.64.42.4)		22 4 (45 9 01 1)	
Glucagon	29.9 (16.4-43.4)	31.3 (13.2-49.4)	33.4 (45.8-21.1)	33.3 (23.5-43.2)
(pg/mL) C pontido	0.2(0.2,0.2)	0.2(0.2,0.2)	(0, 2, (0, 2, 0, 3))	0.2(0.2,0.2)
(nmol/I)	0.3 (0.2-0.3)	0.3 (0.2-0.3)	0.2 (0.2-0.3)	0.2 (0.2-0.3)
$(\mathbf{IIII0I/L})$ TSH $(\mathbf{III/L})$	21(13-29)	$1.5(1.0-2.0)^{b}$	19(12-25)	$1.2(0.9-1.5)^{b}$
Free T3	5.1(4.6.5.6)	5.0(4.4,5.5)	5.1(4.6.5.5)	1.2 (0.5 1.5) $1.8 (1.3 5.3)^{a}$
(nmol/L)	5.1 (4.0-5.0)	5.0 (4.4-5.5)	5.1 (4.0-5.5)	4.0 (4.3-3.3)
Free T4	17 3 (15 7-18 8)	18 1 (16 6-19 6)°	17 2 (15 5-18 8)	177 (164-190) <sup>a,d</sup>
(pmol/L)	1115 (1011 1010)	10.11 (10.0 19.0)	1/12 (10.0 10.0)	1/1/ (10.1/19.0)
Cortisol	337 (254-420)	174 (141-206) <sup>b</sup>	349 (291-406)	173 (117-228) <sup>b</sup>
(nmol/L)		· · · · ·	· · · · ·	· · · · ·
Leptin	0.8 (0.4-1.2)	0.6 (0.2-0.9) <sup>b</sup>	1.1 (0.4-1.7)	0.8 (0.2-1.3) <sup>c,e</sup>
(ng/mL)				
GIP	5.6 [3.1-10.7]	3.8 [2.5-5.4] <sup>b</sup>	6.0 (4.5-7.4)	4.4 (2.3-6.6)
(pmol/L)				
Total GLP-1	28.6 (19.3-38.0)	29.4 (16.7-42.0)	30.2 (18.6-41.8)	30.0 (18.9-41.1)
(pmol/L)				

Table 2. Hormone and metabolite concentrations at baseline or with the ingestion of 200 mg mirabegron without or with 10 mg of bisoprolol

Values are means with 95% confidence interval (CI) in parentheses for normally distributed data and median [interquartile range] for nonparametric data. Two-way ANOVA for repeated-measures with Bonferroni post hoc test. <sup>a</sup>Effect of intervention,  $p \leq 0.05$ 

 $^{b}p < 0.01$ 

<sup>c</sup>p < 0.001

<sup>d</sup>Difference without or with bisoprolol,  $p \le 0.05$ 

 $^{e}p < 0.01$